Mechanisms of resistance to immune checkpoint inhibitors.
about
Next generation of immune checkpoint therapy in cancer: new developments and challenges.Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.Not All Immune Checkpoints Are Created EqualComprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitorB7H3 As a Promoter of Metastasis and Promising Therapeutic TargetBiomarkers for predicting efficacy of PD-1/PD-L1 inhibitorsThe Combined Use of Melatonin and an Indoleamine 2,3-Dioxygenase-1 Inhibitor Enhances Vaccine-Induced Protective Cellular Immunity to HPV16-Associated TumorsPresence of few PD-1-expressing tumor-infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non-small cell lung cancer: An exploratory case seriesLocal angiotensin II contributes to tumor resistance to checkpoint immunotherapyTurn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer ProgressionCo-inhibition of TIGIT, PD1, and Tim3 reverses dysfunction of Wilms tumor protein-1 (WT1)-specific CD8+ T lymphocytes after dendritic cell vaccination in gastric cancerCombination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIVRenin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunitySepsis and Nosocomial Infection: Patient Characteristics, Mechanisms, and Modulation
P2860
Q52653710-C4265CA3-0385-4DFE-A992-06D860A57D16Q55515597-444453E5-A266-433B-BDA6-F4DBC8C9DB27Q55516983-DAB3694F-FA0A-458B-8F99-8E5D339D3E55Q56889626-74984D05-871E-4B21-A6E5-205A773DD737Q57062487-EB17B437-0154-401D-993E-B3B281C52423Q57176931-7C7D0807-8D88-44D6-A86D-EB4C17A66B2DQ58713932-8DAE7DAD-CAD8-49B8-AA2E-A48116DFB67FQ58719262-C4A85C7D-02C7-4298-8CAD-4F79F55F0C97Q58732728-CF8A1EF5-5381-468F-B478-729A31E3B3E7Q58748151-A697F76A-63B4-44CF-AA85-64009376123FQ58780996-76316F90-59F0-40FA-937E-67C54EB17D7EQ58804593-837EF662-7AFE-4FA9-A931-4A6B1FD49957Q59125545-AE01D07E-E380-46CB-B5C9-E6E5E8203DDFQ59125636-ECAD4250-FB3A-4A4C-A708-5AA8F04615A1Q59136322-AF868E16-0832-46FD-B90E-08C34DC02612
P2860
Mechanisms of resistance to immune checkpoint inhibitors.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Mechanisms of resistance to immune checkpoint inhibitors.
@en
Mechanisms of resistance to immune checkpoint inhibitors.
@nl
type
label
Mechanisms of resistance to immune checkpoint inhibitors.
@en
Mechanisms of resistance to immune checkpoint inhibitors.
@nl
prefLabel
Mechanisms of resistance to immune checkpoint inhibitors.
@en
Mechanisms of resistance to immune checkpoint inhibitors.
@nl
P2860
P356
P1476
Mechanisms of resistance to immune checkpoint inhibitors.
@en
P2093
David A Barbie
Russell W Jenkins
P2860
P2888
P356
10.1038/BJC.2017.434
P407
P5008
P577
2018-01-01T00:00:00Z
2018-01-02T00:00:00Z
P6179
1100151420